BridgeBio Pharma (BBIO) EBT (2018 - 2026)

BridgeBio Pharma has disclosed EBT across 9 years of filings, most recently posting -$112.7 million for Q1 2026.

• EBT for Q1 2026 came in at -$112.7 million, up 3.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$675.5 million (down 8.41% YoY), and the FY2025 annual result was -$732.5 million, down 35.1% from the prior year.
• EBT came in at -$112.7 million for Q1 2026 at BridgeBio Pharma, up from -$194.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$19.1 million in Q1 2024 to a low of -$266.2 million in Q4 2024.
• The 5-year median for EBT is -$162.2 million (2023), against an average of -$151.4 million.
• Across the five-year window, EBT soared 86.59% in 2024 and tumbled 514.64% in 2025, its largest moves.
• BridgeBio Pharma's EBT stood at -$145.1 million in 2022, then slumped by 32.37% to -$192.1 million in 2023, then plunged by 38.59% to -$266.2 million in 2024, then rose by 26.85% to -$194.8 million in 2025, then jumped by 42.16% to -$112.7 million in 2026.
• The last three EBT figures came in at -$112.7 million (Q1 2026), -$194.8 million (Q4 2025), and -$186.5 million (Q3 2025), per Business Quant data.